Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Assets (2016 - 2025)

Historic Assets for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $21.7 million.

  • Marker Therapeutics' Assets rose 9921.3% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 9921.3%. This contributed to the annual value of $22.0 million for FY2024, which is 2858.27% up from last year.
  • Per Marker Therapeutics' latest filing, its Assets stood at $21.7 million for Q3 2025, which was up 9921.3% from $14.8 million recorded in Q2 2025.
  • Over the past 5 years, Marker Therapeutics' Assets peaked at $88.4 million during Q1 2021, and registered a low of $10.9 million during Q3 2024.
  • In the last 5 years, Marker Therapeutics' Assets had a median value of $22.0 million in 2024 and averaged $36.3 million.
  • Per our database at Business Quant, Marker Therapeutics' Assets surged by 10604.11% in 2021 and then plummeted by 5803.56% in 2023.
  • Quarter analysis of 5 years shows Marker Therapeutics' Assets stood at $68.1 million in 2021, then plummeted by 49.48% to $34.4 million in 2022, then plummeted by 50.24% to $17.1 million in 2023, then grew by 28.58% to $22.0 million in 2024, then fell by 1.31% to $21.7 million in 2025.
  • Its Assets was $21.7 million in Q3 2025, compared to $14.8 million in Q2 2025 and $17.0 million in Q1 2025.